A phase I clinical study of cancer vaccine with MAGE-A4/Survivin helper peptide for patients with advanced cancers expressing MAGE-A4 or Survivin antigen.
Phase of Trial: Phase I
Latest Information Update: 13 May 2016
At a glance
- Drugs Cancer vaccine (Primary) ; Montanide ISA-51; Picibanil
- Indications Solid tumours
- Focus Adverse reactions
- 19 Nov 2011 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 07 Sep 2011 New trial record